fbpx

NuLids II Peer-Reviewed Study Released by the Journal of Dry Eye Disease!

Dry Eye Relief...in the blink of an eye

NuLids II Peer-Reviewed Study Released by the Journal of Dry Eye Disease!

http://jdryeyedisease.com/index.php/JDED

EFFICACY OF SELF-ADMINISTRATION OF A PERSONAL MECHANICAL EYELID
DEVICE FOR THE TREATMENT OF DRY EYE DISEASE, BLEPHARITIS, AND
MEIBOMIAN GLAND DISEASE

David Schanzlin MD1, John Olkowski MD2, John Coble OD3, Wendy Gross OD1, Michael Dash OD2
1Gordon-Schanzlin New Vision Institute, San Diego, CA
2EyeSight Hawaii Vision Institute, Honolulu, HI
3Eyecare of Greenville, Greenville, TX
Corresponding Author: jolkowski1@gmail.com
Submitted: November 3, 2019. Accepted: December 17, 2019. Published: January 21, 2020.
ABSTRACT
Purpose
A prospective study to evaluate the safety and efficacy of a novel mechanical eyelid device (NuLidsTM by
NuSight Medical, LLC, Rancho Santa Fe, CA) used at home for the treatment of dry eye disease (DED),
blepharitis (anterior and posterior) and meibomian gland disease (MGD).
Methods
Seventy-four (74) eyes of thirty-seven (37) patients were self-treated with the NuLidsTM device at home.
Inclusion criteria included blepharitis, MGD and/or DED. After an initial training session, each eyelid was
treated for 15 seconds (total of 1 minute per treatment session per day). The following tests were collected
before the first treatment and after the final treatment: OSDI survey, BCVA, Tear Osmolarity Test (Tear Lab),
Tear Break Up Time (TBUT), Meibomian Gland Score (MGS), Meibomian Glands Yielding Liquid Secretions
(MGYLS), Sicca Ocular Staining Score. Satisfaction with treatment survey was taken after treatment.
Results
All measured parameters had a statistically significant improvement. Symptoms improved based on an
average decrease in OSDI score from 54.2 ± 19.5 (mean ± SD) to 26.7 ± 18.4 (P < 0.001). Tear osmolarity improved from 315 ± 15.7 to 306 ± 13.9 (P = 0.002). TBUT was noted to improve from pretreatment of 4.8 ± 1.7 seconds to post-treatment of 7.9 ± 4.1 seconds (P < 0.001). MGS improved from 8.9 ± 5.1 to 7.0 ± 5.9 (P = 0.01). MGYLS improved from 8.7 ± 6.2 to 15.8 ± 6.9 (P = 0.002). Sicca Ocular Staining Score improved from 2.7 ± 2.1 to 1.4 ± 1.5 (P = 0.002). There were no adverse events. No corneal or conjunctival trauma. No patients dropped out of the trial due to discomfort. 91% of participants agreed or strongly agreed that the device was easy and convenient to use. Of those previously using manual lid scrubs, 82% felt the NuLids device was easier and more comfortable to use. 89% described little or no discomfort. 95% were satisfied or very satisfied with the overall treatment. J Dry Eye Ocul Sur Dis 3(1):e1-e5; January 21, 2020. This article is distributed under the terms of the Creative Commons Attribution-Non Commercial 4.0 International License. ©2020 Shanzlin.

No Comments

Add your comment